Persistent epithelial defects in repeated corneal transplants

Article

In instances of repeated corneal transplantation, ulcers and persistent epithelial defects are relatively commonplace, according to a study published in the August 2008 issue of Graefe's Archive for Clinical and Experimental Ophthalmology.

In instances of repeated corneal transplantation, ulcers and persistent epithelial defects are relatively commonplace, according to a study published in the August 2008 issue of Graefe’s Archive for Clinical and Experimental Ophthalmology.

 

Shimon Rumelt, MD of the department of ophthalmology, Western Galilee-Nahariya Medical Center, Israel and colleagues conducted a retrospective review of patients (n=80) undergoing multiple corneal transplants and regrafts (n=122) between 1985 and 1998, to evaluate complications at a minimum of six, and an average of 31.5, months after the final surgery.

 

Of the regrafts, 18 were affected by persistent epithelial defects; five had ulcers; and eight had a combination of both persistent epithelial defects and ulcers. Persistent epithelial defects were more likely following cyclocryotherapy for refractory glaucoma. Nine of the 31 regrafts suffering these complications were also positive for bacterial cultures. The graft survival rate was lower in subjects with repeated epithelial defects complicated by ulcers than in any other group, which all had similar levels of graft survival. Of all patients, 10 suffered at least one eyelid abnormality and ocular surface disorder; this was more likely in patients with epithelial defects and/or ulcers than in patients who did not suffer these complications.

 

Although these complications are common occurrences followed repeated keratoplasties and are associated with low graft survival rates, predisposing factors can be treated.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.